Novel Aldosterone Synthase Inhibitor Cuts Albuminuria in Phase II Trial
PHILADELPHIA — An oral investigational aldosterone synthase inhibitor (ASI) cut albuminuria by nearly 40% in people in chronic kidney disease (CKD) in a phase II trial. The 10-mg dose of ASI BI 690517 yielded an average 37.4% (95% CI -52.2 to -18.2%) greater reduction in urine albumin-creatinine ratio (UACR) from baseline to week 14 compared […]
Albuminuria Testing Falling Short in Patients at Risk for CKD
Many cases of albuminuria may be missed in the U.S. due to lack of testing among patients at risk for chronic kidney disease (CKD), a cohort study suggested. Examining electronic health records for nearly 200,000 patients with hypertension or diabetes, only 17.5% underwent albuminuria testing, reported Chi D. Chu, MD, MAS, of the University of […]